COMMON SHARE PURCHASE WARRANT MEDICUS PHARMA LTD.Common Share Purchase • July 15th, 2024 • Medicus Pharma Ltd. • Pharmaceutical preparations • New York
Contract Type FiledJuly 15th, 2024 Company Industry JurisdictionTHIS COMMON SHARE PURCHASE WARRANT (the "Warrant") certifies that, for value received, _____________ or its assigns (the "Holder") is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the "Initial Exercise Date") and on or prior to 5:00 p.m. (New York City time) on _____1 (the "Termination Date") but not thereafter, to subscribe for and purchase from Medicus Pharma Ltd., a corporation organized under the laws of Ontario, Canada (the "Company"), up to ______ common shares (as subject to adjustment hereunder, the "Warrant Shares") of the Company. The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee ("DTC") shall initially be the sole registered holder of this Warrant, s
MEDICUS PHARMA LTD. and Odyssey Transfer and Trust Company, as Warrant Agent Warrant Agency Agreement Dated as of [ ], 2024 WARRANT AGENCY AGREEMENTWarrant Agency Agreement • July 15th, 2024 • Medicus Pharma Ltd. • Pharmaceutical preparations • Minnesota
Contract Type FiledJuly 15th, 2024 Company Industry JurisdictionWARRANT AGENCY AGREEMENT, dated as of [ ], 2024 ("Agreement"), between Medicus Pharma Ltd., a corporation organized under the laws of Ontario, Canada (the "Company"), and Odyssey Transfer and Trust Company, as warrant agent, a corporation organized under the laws of Minnesota (the "Warrant Agent").
MANAGEMENT AGREEMENTManagement Agreement • July 15th, 2024 • Medicus Pharma Ltd. • Pharmaceutical preparations
Contract Type FiledJuly 15th, 2024 Company IndustryThis confidential Agreement (the "Agreement") is made as of October 18, 2023 by and between Medicus Pharma Ltd (MDCX), and Rbx Capital, LP, ("RBx").